The trial enrolled 76 children with severe IGFD and followed them for up to 8 years on twice-daily subcutaneous mecasermin administration, with growth velocity, height standard-deviation score, and adverse events as primary endpoints
Professional guidance improves safety, supports your confidence, and helps you reclaim energy for the life you loveno more feeling alone or frustrated on your journey
Our experienced legal team is committed to holding pharmaceutical companies accountable for the safety of their products and ensuring that victims receive the compensation they deserve
Less common side effects can be headaches, dizziness, and low blood sugar
This blog explores the relationship between weight, back pain, and how GLP-1 assisted weight-loss may offer a transformative solution for millions
Brain Health Emerging research suggests potential benefits for memory and cognitive function